Mammogram Pretreatment With Ulipristal Acetate

Conditions

• Breast Density
• Mammography Screening

Eligibility Criteria

Sex

FEMALE

Age

18 Years - 50 Years

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo blood sample collection
• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Mammogram — PROCEDURE
  Participants will undergo their standard of care mammogram.
• Survey Administration — OTHER
  Ancillary studies
• Ulipristal Acetate — DRUG
  Given orally

Study Details

This phase II trial tests whether taking ulipristal acetate prior to a mammogram decreases breast density for people with a history of extremely dense breast tissue. One limitation to breast cancer screening with mammography is dense breast tissue, which decreases the sensitivity of screening as breast density masks cancer and precancerous lesions. Ulipristal acetate lowers the amount of progesterone made by the body which may temporarily decrease the density of the breast tissue, allowing for a more accurate mammogram for people with extremely dense breast tissue.

Key Dates

Start date

Apr 2, 2026

Status verified

Feb 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

26 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Diagnostic (uliprostal acetate)
  Patients receive ulipristal acetate PO every 5 days for 4 doses in the absence of unacceptable toxicity. Patients then undergo a mammogram. Patients also undergo MRI and blood sample collection throughout the study.

Primary Outcome Measure

Difference in percent dense area [ Time Frame: From baseline mammogram to study day 20 mammogram ]

Locations (1)

Find similar trials in Portland, OR

Related Studies

• Breast Cancer Screening Decision Aid
  Recruiting · Yale University · New Haven, Connecticut